Anuj D. Patel, MD
Department of Neuro-Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | Brown University, Providence, Rhode Island, US, M.D |
| 2013 | Brown University, Providence, Rhode Island, US, Cognitive Neuroscience, Sc.B |
Postgraduate Training
| 2021-2023 | Fellow, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2018-2021 | Resident, Neurology, Boston University, Boston, Massachusetts |
| 2017-2018 | Intern, Internal Medicine, Boston University, Boston, Massachusetts |
Licenses & Certifications
| 2023 | United Council for Neurologic Subspecialties |
| 2023 | Texas Medical Board |
| 2021 | American Board of Neurology and Psychiatry |
| 2021 | Massachusetts Board of Registration in Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Patient Safety & Quality Officer, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Associate Rotation Site Director, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Honors & Awards
| 2022 | Trainee Leadership Certificate, MD Anderson Leadership Institute |
| 2017 | Medical Student Prize for Excellence, American Academy of Neurology |
| 2017 | Stanley Aronson Prize in Neuroscience, Brown University |
| 2013 | Premium for Excellence in Cognitive Neuroscience, Brown University |
| 2013 | Elected to Phi Beta Kappa |
| 2013 | Elected to Sigma Xi |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Trial in Progress - A phase I/II trial of ivonescimab, a novel VEGF/PD-1 bispecific antibody, in recurrent glioblastoma. Invited. Cancer Neuroscience Program (CNP) Seminar Series. Houston, Texas, US.
- 2024. Adolescent and Young Adulty (AYA) Considerations in Neuro-Oncology. Invited. Department of Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2022. Health Disparities in Neuro-Oncology. Invited. Department of Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2022. Sexual and Reproductive Health in Patients with Brain Tumors. Invited. Department of Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
Regional Presentations
- 2025. Neurotoxicity of CAR-T Cell Therapy: A Neurologist's Primer. Invited. Clinical Neuroscience Grand Rounds - Virtual. Boston, MA, US.
National Presentations
- 2025. Trial in Progress - A phase I/II trial of ivonescimab, a novel VEGF/PD-1 bispecific antibody, in recurrent glioblastoma. Conference. 2025 Annual American Society of Clinical Oncology (ASCO) Meeting. Chicago, IL, US.
International Presentations
- 2023. Upfront versus deferred treatment in lower grade IDH-mutant gliomas: a single center retrospective analysis. Poster. 28th Annual Meeting of the Society for Neuro-Oncology (SNO). Vancouver, CA.
Selected Publications
Peer-Reviewed Articles
- Nadjarian, A, Leclair, J, Mahoney, TF, Awtry, EH, Bhatia, JS, Caruso, LB, Clay, A, Greer, DM, Hingorani, KS, Horta, LF, Ibrahim, M, Ieong, MH, James, T, Kulke, MH, Lim, R, Lowe, RC, Moses, JM, Murphy, J, Nozari, A, Patel, A, Silver, B, Theodore, AC, Wang, RS, Weinstein, E, Wilson, SA, Cervantes-Arslanian, AM. Validation of a Crisis Standards of Care Model for Prioritization of Limited Resources During the Coronavirus Disease 2019 Crisis in an Urban, Safety-Net, Academic Medical Center. Critical care medicine 49(10):1739-1748, 2021. e-Pub 2021. PMID: 34115635.
Other Articles
- Yeboa DN, Whitfield BT, Lin R, Ejezie CL, Swanson TA, Beckham TH, Wang C, De B, Perni S, Tom MC, Li J, McGovern SL, Harrison R, Majd NK, Puduvalli VK, Aaroe AE, Loghin M, O’Brien BJ, Patel AD, Patel CB, Wefel JS, Taslicay CA, Gule-Monroe M, Paulino AC, McAleer MF, Grosshans DR, Ghia AJ, Jiang W, Chung C, Maor M, Yang C, Gubbiotti MA, Kamiya-Matsuoka C, Ballester LY, Weathers S, Huse JT Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy. J Neurooncol 176(72), 2025. PMID: 41191157.
Abstracts
- Patel, Anuj. Dual Targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma. 2025 American Society of Clinical Oncology (ASCO) conference.
- Patel AD. Upfront versus deferred treatment in lower grade IDH-mutant gliomas: a single center retrospective analysis. 28th Annual Meeting for the Society of Neuro-Oncology (SNO).
Book Chapters
- Patel AD, Sartor EA. Prognostication in Neuro-Oncology and Neurological Complications of Hemato/Oncological Diseases. In: Neuroprognostication in Critical Care. Cambridge University Press, 2024.
Patient Reviews
CV information above last modified March 25, 2026